mutations, in whom rituximab seems to acquire minor additional benefit.59 Other genomic subgroups, which include sufferers with BIRC3This methylation profile is presently obtained on the MBL stage3 and continues to be fairly stable with time. However, some CLL have intratumor variability in specific areas, which may alter the expression of several